Research status and progress of laboratory diagnostic tests for intraocular lymphoma
10.3760/cma.j.cn511434-20210412-00190
- VernacularTitle:眼内淋巴瘤实验室诊断性检查的研究现状和进展
- Author:
Bixuan QIN
1
;
Yanchun ZHANG
;
Ziwei KANG
Author Information
1. 西安市人民医院（西安市第四医院）陕西省眼科医院, 西北大学附属人民医院, 西安市眼底病研究所, 西安 710004
- Keywords:
Intraocular lymphoma;
Diagnosis;
Ocular fluid;
Ocular cytokine;
MYD88;
Metagenomic deep sequencing;
Review
- From:
Chinese Journal of Ocular Fundus Diseases
2023;39(1):68-73
- CountryChina
- Language:Chinese
-
Abstract:
Intraocular lymphoma (IOL) is a rare lymphocytic malignancy. The gold standard for the definite diagnosis remains histopathologic examination of the ocular specimen. But cytologic confirmation of malignant lymphoma cells in vitreous or chorioretinal specimens is challenging and dependending on highly skilled cytopathologist, due to the sparse cellularity and specimen degeneration. Consequently, false-negative rates arecommon, which delays diagnosis and treatment seriously. Because of the limited diagnostic capacity of cytology, other adjunct diagnostic tools have been developed. Additional procedures that may support IOL diagnosis include flow cytometry, immunocytochemistry, cytokines study with identification of interleukin (IL)-10 and IL-6 level, and polymerase chain reaction amplification. And more recently, new techniques of mutational analysis have been validated for the diagnosis of vitreoretinal lymphoma (VRL) and may represent a helpful diagnostic tool for the detection of early cases. Metagenomic deep sequencing technology may provide an important basis for IOL diagnosis and personalized treatment. In the future, it is expected to deepen the understanding of IOL disease phenotypes at the molecular level, discover new target therapies, monitor response to treatment, and detect intraocular recurrences. These may offer insights into how we might create a tailored therapeutic approach for each patient's VRL in the future.
